Novartis Ag (NVS) Asset Writedowns and Impairment (2009 - 2014)

Novartis Ag has disclosed Asset Writedowns and Impairment across 6 years of filings, most recently posting -$682.0 million for Q4 2014.

• In Q4 2014, Asset Writedowns and Impairment fell 498.25% year-over-year to -$682.0 million; the TTM figure through Dec 2014 stood at -$1.7 billion (up 11.88% YoY), while the FY2023 annual figure was -$44.0 million, down 1366.67% from the prior year.
• Asset Writedowns and Impairment came in at -$682.0 million for Q4 2014 at Novartis Ag, down from -$114.0 million in the prior quarter.
• In the past five years, Asset Writedowns and Impairment ranged from a high of -$114.0 million in Q4 2013 to a low of -$911.0 million in Q4 2010.
• Average Asset Writedowns and Impairment over 5 years is -$521.8 million, with a median of -$619.0 million recorded in 2011.
• Year-over-year, Asset Writedowns and Impairment slumped 3403.85% in 2010 and jumped 59.72% in 2013.
• Over 5 years, Asset Writedowns and Impairment stood at -$911.0 million in 2010, then surged by 32.05% to -$619.0 million in 2011, then jumped by 54.28% to -$283.0 million in 2012, then jumped by 59.72% to -$114.0 million in 2013, then tumbled by 498.25% to -$682.0 million in 2014.
• Per Business Quant data, the three most recent Asset Writedowns and Impairment figures were -$682.0 million in Q4 2014, -$114.0 million in Q4 2013, and -$283.0 million in Q4 2012.